Read More

Analysts Eye Summit Therapeutics’ Ivonescimab As Potential Challenger To Merck’s Keytruda in Lung Cancer Treatment

Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in 2024 and a $5 billion deal add to the optimism, signaling potential share price growth ahead.

MRK

Read More

Wipro GE Healthcare Sets Sight on India’s Healthcare Growth with $960M Investment

Wipro GE Healthcare plans to invest ₹80 billion ($960 million) in its Indian facilities over 5 years. Focused on bolstering local manufacturing aligned with "Make in India," the investment targets PET CT scan devices for global export. Additionally, the company aims to produce CT scanners and MR breast coils domestically.

GEHC

Read More

Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly

Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its potential to preserve muscle mass, boost metabolism, and induce weight loss.

BHVN